Clinical efficacy and tolerance of an extract of green-lipped mussel (<i>Perna canaliculus</i>) in dogs presumptively diagnosed with degenerative joint disease

Pollard, Bette S.; Guilford, W. Grant; Ankenbauer-Perkins, K L; Hedderley, Duncan I.

doi:10.1080/00480169.2006.36622

Cited by 56 publications

(52 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Possibly, the lack of statistical significance of the polydextrose effects is caused by insufficient statistical power in combination with placebo effects rather than by an inefficacy of the supplement. The double-blind nature of the trial excluded any observer bias, but it is well-known that placebo effects occur in double-blind studies on canine osteoarthritis (Dobenecker et al, 2002;Gingerich and Strobel, 2003;Innes et al, 2003;Pollard et al, 2006). Likewise, in this study the clinical signs of the control animals were improved during the course of the study as observed by the owners.…”

Section: Discussionsupporting

confidence: 54%

Impact of Dietary Polydextrose on Clinical Signs of Canine Osteoarthritis

Beynen¹

2011

American Journal of Animal and Veterinary Sciences

View full text Add to dashboard Cite

Problem statement:Osteoarthritis is an inflammatory joint disease associated with loss of cartilage matrix. There is suggestive evidence that the intake of polydextrose fiber has anti-inflammatory activity. It was reasoned that polydextrose may have a positive influence on canine osteoarthritis. Approach: A double-blind, placebo-controlled trial with privately owned dogs was carried out to assess the efficacy of STA-LITE® polydextrose in the treatment of osteoarthritis. With the use of a questionnaire, five clinical signs were evaluated by the owners. For a period of 8 weeks, the dogs received a complete dry food without or with 3% polydextrose. There were 16 control and 19 test dogs. Results:The baseline values of clinical scores for swelling of joints, stiffness and lameness indicated that the severity of osteoarthritis was much less in test dogs than in the controls. The initial scores for activity and pain were similar in two groups. Comparing the changes in clinical scores over time between control and test dogs would be biased by the difference in baseline severity of osteoarthritis. On strict terms, a maximum number of pairs of matched control and test dogs was formed for each clinical sign. It was found that all five clinical signs showed more group-mean improvement in the dogs fed the diet containing polydextrose than in those given the control diet. The difference between the pooled group-mean changes of the control and test dogs was statistically significant. As an overall index of the improvement of osteoarthritis, the sum of changes for the five clinical variables was calculated. Polydextrose was found to induce a marked improvement of osteoarthritis: The polydextrose-mediated increase in the osteoarthritis improvement index was 57%. Conclusion: Polydextrose can be considered safe and it is suggested that a dose of 3% in a dry food can be beneficial for dogs with osteoarthritis.

show abstract

Section: Discussionsupporting

confidence: 54%

Impact of Dietary Polydextrose on Clinical Signs of Canine Osteoarthritis

Beynen¹

2011

American Journal of Animal and Veterinary Sciences

View full text Add to dashboard Cite

show abstract

“…Because of the open nature of the study and the absence of a placebo group, the observed decrease in clinical signs of joint disorders cannot be taken as evidence for a beneficial effect of beta-1,3/1,6-glucans. It is very likely that placebo effects occur when evaluating the clinical signs of dogs with osteoarthritis (Dobenecker et al, 2002;Gingerich and Strobel 2003;Innes et al, 2003;Pollard et al, 2006). This study readdresses the efficacy of a preparation of beta-1,3/1,6-glucans in the treatment of canine osteoarthritis.…”

Section: Introductionmentioning

confidence: 99%

Influence of Dietary Beta-1,3/1,6-Glucans on Clinical Signs of Canine Osteoarthritis in a Double-Blind, Placebo-Controlled Trial

Beynen¹

2010

American Journal of Animal and Veterinary Sciences

View full text Add to dashboard Cite

Problem statement: There are indications for a beneficial effect of beta-1,3/1,6-glucans on the clinical signs of dogs with osteoarthritis. Data from a controlled trial were necessary to prove or disprove the indications. Approach: A double-blind, placebo-controlled trial with privately owned dogs was carried out to assess the efficacy of a preparation of beta-1,3/1,6-glucans in the treatment of osteoarthritis. With the use of a questionnaire, the clinical signs were evaluated by the owners. For a period of 8 weeks, the test dogs daily received a complete dry food without or with 800 ppm beta-1,3/1,6-glucans. There were 23 dogs per experimental group. Results: When compared with the baseline values, the administration of beta-1,3/1,6-glucans significantly improved activity (vitality) and significantly reduced stiffness, lameness and pain. In the placebo group there only was a significant change in the clinical signs of stiffness. When the changes over time for the two groups were compared, there were no statistically significant differences, but the test group showed greater numerical improvement as to the scores for activity, stiffness, lameness and pain. Conclusion: Beta-1,3/1,6-glucans can be considered safe and it is suggested that a dose of 800 ppm in a dry food would be beneficial for dogs with osteoarthritis.

show abstract

“…In that study, dogs weighing 5 to 15 kg received 3 tablets/day, 16 to 20 kg dogs received 5 tablets/day, 21 to 25 kg dogs received 6 tablets/day, 26 to 45 kg dogs received 8 tablets/day, and 46 to 65 kg dogs received 9 tablets/day. The study showed that 67% of the dogs in the GLM group had improved clinical assessment scores compared to 41% in the placebo (P = 0.018) after 56 days (Pollard et al, 2006). Finally, a study was conducted on dogs suffering from OA (n = 23), with dogs fed a control diet for 30 days before being switched to a test diet enriched with GLM for 60 days (Rialland et al, 2013).…”

Section: Green-lipped Musselmentioning

confidence: 99%

“…All three scores were reduced (P < 0.05) by 36, 33, and 34%, respectively for the GLM group on day 50 compared to baseline (Servet et al, 2006). A study conducted by Pollard et al (2006) tested a GLM supplement with 125 mg/tablet in dogs with OA over 56 days (n = 81; mean age 8.5 years). In that study, dogs weighing 5 to 15 kg received 3 tablets/day, 16 to 20 kg dogs received 5 tablets/day, 21 to 25 kg dogs received 6 tablets/day, 26 to 45 kg dogs received 8 tablets/day, and 46 to 65 kg dogs received 9 tablets/day.…”

Section: Green-lipped Musselmentioning

confidence: 99%

See 1 more Smart Citation

Effects of dietary calcium fructoborate supplementation on joint comfort and flexibility and serum inflammatory markers in dogs with osteoarthritis

Price¹,

Godoy²,

Harper³

et al. 2017

Journal of Animal Science

View full text Add to dashboard Cite

Symptoms of osteoarthritis (OA) afflict approximately 20% of adult dogs in NorthAmerica. Clinical signs consistent with OA include decreased range of motion of a joint, reduced physical activity, difficulty climbing stairs or onto furniture, and a reduced ability to rise from a lying position. A safe and effective nutraceutical supplement may benefit dogs suffering from OA. Calcium fructoborate (CFB), a mimetic of a naturally occurring molecule, has previously been reported to be safe and effective in humans with joint problems. The objective of this randomized, double-blinded, placebo-controlled study was to evaluate the short-term effects of CFB alone, or in combination with a blend of glucosamine hydrochloride (GH) and chondroitin sulfate (CS), on gait analysis, goniometry, serum inflammatory markers, and owner perception of pain in client-owned dogs. Sixty-four dogs with joint discomfort were recruited and 59 dogs (mean age = 8.42 ± 0.37 yr.; mean BW = 31.11 ± 1.28 kg) completed the study. All procedures were approved by the University of Illinois Institutional Animal Care and Use Committee, and pet owners signed an informed consent prior to study initiation. Dogs were randomly assigned to one of four treatments: placebo (60 mg fructose; n = 15), low dose (69 mg CFB; n = 14), high dose (127 mg CFB; n = 14), or combination (69 mg CFB, 500 mg GH and 200 mg CS; n = 16).Treatments were provided once daily as dietary supplements. Small dogs weighing up to 22.9 kg received 1 capsule/day, while large dogs weighing 23 to 50 kg received 2 capsules/day for 28 days. A physical examination, radiographs, goniometry measurements, gait analysis, blood sample collection, and the canine brief pain inventory (CBPI) questionnaire were performed and administered on days 0 and 28. As expected, a majority (69%) of the dogs were overweight or obese, with a body condition score (BCS) > 6 on a 9-point scale. Dogs fed the low dose (-2.93) and high dose (-2.21) of CFB were shown to improve (P < 0.05) in their ability to rise from a iii lying position from day 0 to day 28 compared to dogs fed the placebo (0.00), but no difference was observed for dogs fed the combination treatment. Dogs assigned the low dose of CFB also tended to have an improved pain severity score (PSS; -1.46; P = 0.08) and pain at its worst score (-2.14; P = 0.06) from day 0 to day 28 compared to dogs fed the placebo (0.05 and 0.00, respectively). Dogs fed the high dose of CFB had a greater increase (P = 0.05) in serum concentration of soluble receptor for advanced glycation end products (sRAGE) from day 0 to day 28 (7.88 ng/mL) compared to dogs fed the placebo (0.83 ng/mL). All blood metabolites were within reference range except total alkaline phosphatase and corticosteroid-induced alkaline phosphatase, which started and ended at concentrations greater than the upper reference range.Dogs assigned the high dose of CFB tended to have a greater reduction (P = 0.07) in serum chloride from day 0 to day 28 (-1.64 mmol/L) compared to dogs fed the low dose of ...

show abstract

Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease

Abstract: GLME had a beneficial effect on the clinical signs of dogs presumptively diagnosed with mild-to-moderate DJD. Long-term therapy may be required before improvement is apparent.

Cited by 56 publications

References 11 publications

Impact of Dietary Polydextrose on Clinical Signs of Canine Osteoarthritis

Impact of Dietary Polydextrose on Clinical Signs of Canine Osteoarthritis

Influence of Dietary Beta-1,3/1,6-Glucans on Clinical Signs of Canine Osteoarthritis in a Double-Blind, Placebo-Controlled Trial

Effects of dietary calcium fructoborate supplementation on joint comfort and flexibility and serum inflammatory markers in dogs with osteoarthritis

Contact Info

Product

Resources

About